Points of Pride

The University of Maryland School of Pharmacy globally engages and leads education, pharmacy practice, scientific research, and pharmapreneurial initiatives to collaboratively and equitably improve the health of society.

We are internationally recognized for:

empowering learners and graduating visionary leaders
pioneering social impact and business innovation through Pharmapreneurship
listening to all voices to equitably enrich the lives of our internal and external communities
positively influencing the delivery of convenient and affordable health care
leveraging pharmaceutical expertise and relentlessly collaborating to solve scientific, clinical, and social problems that matter to all citizens of the world

Research

#12 in funded research grants out of more than 140 schools of pharmacy in the country by AACP
$36.5 million in 2024 — NIH, NSF, FDA, CDC, Agency for Healthcare Research and Quality, PhRMA Foundation, and the pharmaceutical industry
$50 million — five-year renewal of the Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI) by the FDA
$46 million — Center for Translational Medicine is co-PI on grant from the Defense Advanced Research Projects Agency to create an artificial blood product
$5 million — FDA funding for the Center for Research on Complex Generics in partnership with the University of Michigan College of Pharmacy
404 peer-reviewed publications in 2025
15 patents in 2025

Major Leadership Bequest

The University of Maryland School of Pharmacy has received an eight-figure leadership bequest to propel Pharmapreneurship, education, research, practice, and service.

Center for Translational Medicine to Aid Artificial Blood Research

Three faculty members from the Center for Translational Medicine will be part of an ambitious research collaboration that aims to create an artificial, shelf-stable blood product. The $46.4 million four-year grant is funded by the Defense Advanced Research Projects Agency.

38,000 patients, 35 practice settings, 190,300 student hours of pharmacy services.
$10 million contract from the state of Maryland for pharmacy services at state mental health facilities and to oversee review of mental health medications for children on Medicaid.
Center for Innovative Pharmacy Solutions’ (CIPS) E-Health Center provides comprehensive medication management services to health systems, physicians’ offices, and insurers through a HIPAA-compliant app and telehealth and telephonic platforms.
Pharmacy faculty experts were instrumental in a groundbreaking FDA vote to remove a longstanding barrier to patients being prescribed clozapine, a medication used to treat schizophrenia and schizoaffective disorder.
Peter Lamy Center on Drug Therapy and Aging improves the lives of older adults by optimizing medication safety and use through practice, research, and education, and a leader within the University of Maryland, Baltimore’s Age-Friendly University initiative.
PATIENTS Program boasts an interdisciplinary team of community partners and researchers working for health equity in West Baltimore by engaging underserved populations and received $9.4 million grant to start a health equity research hub at UMB.
Faculty member serving as president-elect of the American Pharmacists Association, the first faculty member from UMSOP, the first female from Maryland to serve as president of APhA, and the first pharmacist from Maryland to be elected since 1930..
Maryland Poison Center — 50 years, 2.5 million calls handled by pharmacists and nurses with more than 210 years of combined experience. Expanded to included Washington, D.C. in 2025.

Maryland Poison Center Celebrates 50th Anniversary

For the last five decades, the Maryland Poison Center has served the state and nation. The center, which is part of the Department of Pharmacy Practice, Sciences, and Health Outcomes Research at the University of Maryland School of Pharmacy, has handled more than 2.5 million calls by pharmacists and nurses and employs poison specialists with more than 210 years of combined experience.

Learn More

Education

11 academic programs, 10 dual degrees, 850 PharmD, PhD, MS, and graduate certificate students.
MS in Artificial Intelligence for Drug Development - first of its kind in the world – providew students with cutting-edge skills in natural language processing and machine learning to accelerate innovation at every stage of drug development.
UMSOP’s PhD in Palliative Care – the nation’s first - graduated its inaugural class in 2025.
$1 million gift for the Felix A. Khin Maung-Gyi, BSP ’83, PharmD, MBA, Endowed Memorial Professorship in Pharmapreneurship
$30,000 Gyi Scholarship — a full year of tuition for a pharmacy student who has demonstrated a commitment to pharmapreneurship. Largest scholarship in School history.
Nine $10,000 Wagner Scholarships — awarded to students in the Pharmapreneurship pathway, providing a platform to explore business ideas and ventures.
Partnership with xFoundry Alliance expands student opportunities in innovation.
MS in Pharmaceutical Sciences — every student completes a six-month biopharmaceutical internship in the pharmaceutical industry, including at AstraZeneca and the National Institute of Standards and Technology, leading to employment opportunities.
Fellowship programs with AstraZeneca for PhD in Pharmaceutical Health Services Research students and PharmD students providess real-world experience for students seeking to improve patient outcomes.
Home of the nation’s first MS in Medical Cannabis Science and Therapeutics, with more than 500 graduates in the program’s first five years.
Alumni Impact — More than 7,600 alumni; founders of companies such as CorrectRx Pharmacy Services, Pricklee Cactus Water, OneWorld Health, Medicines360, Merck Sharpe and Dohme, Noxell Corporation, Nutramax Labs, and King Pharmaceuticals.